Anti-TREM-2 Antibody, clone 10H4.2

Format: Purified

Protein G Purified

Purified mouse monoclonal IgG1κ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Evaluated by Western Blotting in human spleen tissue lysate.

Western Blotting Analysis: 0.5 µg/mL of this antibody detected TREM-2 in 10 µg of human spleen tissue lysate.

Anti-TREM-2 Antibody, clone 10H4.2 is an antibody against TREM-2 for use in Western Blotting, Immunohistochemistry (Paraffin).

Immunohistochemistry Analysis: A 1:50 dilution from a representative lot detected TREM-2 in human bone marrow, spleen and cerebellum tissue sections.

Research Category
Neuroscience

Research Sub Category
Neuroinflammation & Pain

Clone 10H4.2 recognizes a cytoplasmic domain epitope that is not present in the spliced isoforms 2&3 reported by UniProt (Q9NZC2).

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Triggering receptor expressed on myeloid cells 2 (UniProt Q9NZC2; also known as TREM-2, Triggering receptor expressed on monocytes 2) is encoded by the TREM2 gene (Gene ID 54209) in human. TREM2 is an Ig-like V-type receptor expressed by populations of myeloid cells in the central nervous system and periphery. TREM2 is highly expressed in microglia, where it, along with its adaptor protein DAP12, regulates inflammatory cytokine release and phagocytosis of apoptotic neurons. Apolipoprotein E (apoE) is reported to function as a high-affinity TREM2 ligand. ApoE binding enhances the phagocytosis of apoptotic N2a cells by primary microglia cells, and greatly reduced ApoE binding is seen with AD-associated TREM2 R47H mutatant. TREM2 is produced with a signal peptide sequence (a.a. 1-18), the removal of which yields the mature single-transmembrane (a.a. 175-195) protein with a large extracellular region (a.a. 19-174) that contains the V-type Ig-like domain (a.a. 29-112) and a cytoplasmic tail (a.a. 196-230). The short cytoplasmic tail contains no signaling motifs and relies on its association with the immunoreceptor tyrosine-based activation motif- (ITAM-) containing TYROBP for signal transduction. TREM2 gene mutations and polymorphisms are linked to several neurological disorders, including Alzheimer′s disease (AD), frontotemporal dementia (FTD), Parkinson′s disease (PD), and Nasu-Hakola disease (a.k.a. PLOSL or polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy).

~30 kDa oberved. Target band size appears larger than the calculated moleuclar weights of 25.45 kDa (pro-form) and 23.45 kDa (mature form) due to glycosylation. Uncharacterized band(s) may appear in some lysates.

Epitope: Cytoplasmic domain.

KLH-conjugated linear peptide corresponding to a cytoplasmic domain sequence of human TREM-2.

Concentration: Please refer to lot specific datasheet.

Stable for 1 year at 2-8°C from date of receipt.